Search for Stocks Search for IPO Search for Indices

Customer Portal

EMI Card

Download

Offers

BAJAJ FINSERV DIRECT LIMITED

Open Your FREE Demat Account Now!

Apply Now

Fundamentals Financials Shareholding About Company Peer Comparison Latest News FAQs

Prevest Denpro Ltd. Share Price

NSE

BSE

BSE : 543363

Sector : Healthcare

N/A

indicator

1D

1M

3M

6M

1Y

5Y

Financials

Particulars	QTR FY (₹ in Millions)	Annual FY (₹ in Millions)
Net sales	149.26	564.4
Expenses	N/A	N/A
PBT	57.55	214.14
Operating profit	0.0	0.0
Net profit	44.64	161.24

Shareholding Pattern

Promoters (% Holding)

73.60%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

24.98%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.65%

About Prevest Denpro Ltd.

Founded	1999
Managing Director	Atul Modi

Peer Comparision

Stocks Name	Market Cap (Cr)(₹)	Market Price (₹)	52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd.	4,36,858.91	1,820.75	1,548.00 - 1,548.00
Divi's Laboratories Ltd.	1,76,617.57	6,650.75	5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd.	1,44,717.58	4,293.00	3,101.60 - 3,101.60
Apollo Hospitals Enterprise Ltd.	1,11,737.93	7,760.00	6,677.50 - 6,677.50
Cipla Ltd.	1,07,721.85	1,333.55	1,165.70 - 1,165.70
Lupin Ltd.	1,07,143.97	2,344.50	1,836.80 - 1,836.80
Dr. Reddy's Laboratories Ltd.	1,06,080.73	1,270.95	1,129.40 - 1,129.40
Max Healthcare Institute Ltd.	97,300.05	999.75	903.00 - 903.00
Mankind Pharma Ltd.	95,803.01	2,320.65	1,909.70 - 1,909.70
Zydus Lifesciences Ltd.	91,753.45	919.85	835.50 - 835.50

Latest News

Apr

27

2026

EQUITY Posted on Apr 27^th 2026

Prevest Denpro informs about change in directorate

Pursuant to Regulation 30 of SEBI Listing Regulations, Prevest Denpro has informed that Pardeep Gandotra (DIN: 08733719) had ceased to hold office as Independent Directors of the Company upon completion of tenure with effect from the closure of business hours on April 26, 2026. Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular no. HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 is annexed. The said information shall also be made available on the website of the Company.

The above information is a part of company’s filings submitted to BSE.

Read More

May

5

2026

EQUITY Posted on May 5^th 2026

Emmessar Biotech & Nutrition informs about board meeting

Emmessar Biotech & Nutrition has informed that a meeting of the Board of Directors of the Company will be held on Tuesday the May 12, 2026, at Mumbai, To consider and approve Audited Financial Results of the Company for the year ended 31st March, 2026. Further, pursuant SEBI (Prohibition of Insider Trading), Regulations, 2015, as amended from time to time the Trading Window, as informed to the exchange vide letter dated 30.03.2026 in respect of trading in equity shares of the Company will remain closed up to May 14, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More

May

5

2026

EQUITY Posted on May 5^th 2026

Emcure Pharmaceuticals informs about change in management

Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).

The above information is a part of company’s filings submitted to BSE.

Read More

May

5

2026

EQUITY Posted on May 5^th 2026

Sanofi Consumer Healthcare India informs about disclosures

Sanofi Consumer Healthcare India has informed that the Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon India Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

Read More

May

5

2026

EQUITY Posted on May 5^th 2026

Shelter Pharma informs about receipt of order

Pursuant to Regulation 30 read with Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Shelter Pharma has informed that the Company has received repeat international purchase orders from an existing overseas customer, Taha Drugs & Chemicals Co. Ltd in the normal course of business.

The above information is a part of company’s filings submitted to BSE.

Read More

Sign in to Unlock Offers!

STEP 1/2

Open Demat Account today!

Mobile Number

Enter mobile number

Frequently Asked Questions

What is the current share price of Prevest Denpro Ltd. ?

The current share price of Prevest Denpro Ltd. is ₹428.00 as of 2026-05-05.

What is the Market Cap of Prevest Denpro Ltd. Share?

The market capitalisation of Prevest Denpro Ltd. is ₹513.73 as of 2026-05-05.

What is a 1 year return for Prevest Denpro Ltd. ?

The 1-year return of Prevest Denpro Ltd. is -30.95% as of 2026-05-05.

What is the P/E Ratio of Prevest Denpro Ltd. Share?

The P/E ratio of Prevest Denpro Ltd. is 28.34 as of 2026-05-06.

What is the 52 Week High and Low of Prevest Denpro Ltd. ?

The 52-week high and low of Prevest Denpro Ltd. are ₹622.05 and ₹318.15, respectively, as of 2026-05-05.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.

STEP 1/2

Open a Demat Account today!

Mobile Number Enter Valid Mobile Number

Indices : Nifty 50 Nifty Bank Nifty Financial Services Nifty Next 50 Nifty Midcap 100 BSE Sensex India Vix

Stocks : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Home

Shopping

Personal Loan

My Accounts

Explore